Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis

Silje Stokke Kvistad; Kjell-Morten Myhr; Trygve Holmøy; Jūratė Šaltytė Benth; Stig Wergeland; Antonie G Beiske; Kristian S Bjerve; Harald Hovdal; Rune Midgard; Jørn V Sagen; Øivind Torkildsen

doi:10.1016/j.jneuroim.2018.07.011

Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis

J Neuroimmunol. 2018 Oct 15:323:73-77. doi: 10.1016/j.jneuroim.2018.07.011. Epub 2018 Jul 24.

Authors

Affiliations

¹ Department of Immunology and Transfusion Medicine, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway. Electronic address: sgns@helse-bergen.no.
² Department of Clinical Medicine, University of Bergen, Bergen, Norway; Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway.
³ Department of Neurology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
⁴ Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Health Services Research Unit, Akershus University Hospital, Lørenskog, Norway.
⁵ Neurology Group, Oslo, Norway.
⁶ Department of Medical Biochemistry, St. Olav's Hospital, Trondheim University Hospital, Norway; Clinic of Laboratory Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway; Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, Trondheim, Norway.
⁷ Department of Neurology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
⁸ Department of Neurology, Molde Hospital, Norway; Unit for Applied Clinical Research, Norwegian University of Science and Technology, Trondheim, Norway.
⁹ Department of Clinical Medicine, University of Bergen, Bergen, Norway; Hormone Laboratory, Department of Laboratory Medicine and Pathology, Haukeland University Hospital, Bergen, Norway.
¹⁰ Department of Clinical Medicine, University of Bergen, Bergen, Norway; Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Bergen, Norway.

PMID: 30196837
DOI: 10.1016/j.jneuroim.2018.07.011

Abstract

Adipokines secreted by fatty tissue have inflammatory properties and are suggested biomarkers of MS disease activity. To assess this, 88 MS patients were followed with nine repeated measurements of leptin and adiponectin and 12 magnetic resonance imaging (MRI) scans for two years; six months without any immunomodulatory treatment followed by 18 months during interferon-beta (IFNB) treatment. Serum levels of leptin dropped and adiponectin increased upon initiation of IFNB-therapy, but were not associated with clinical or MRI disease activity or with treatment response. Our findings indicate that leptin and adiponectin are not useful as biomarkers of MS disease activity.

Keywords: Adipokines; Interferon-beta treatment; MRI disease activity; Multiple sclerosis; No evidence of disease activity; Treatment response.

Publication types

Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adiponectin / blood*
Biomarkers / blood
Cohort Studies
Disease Progression*
Double-Blind Method
Female
Humans
Immunologic Factors / therapeutic use
Interferon-beta / therapeutic use*
Leptin / blood*
Magnetic Resonance Imaging / trends
Male
Multiple Sclerosis / blood*
Multiple Sclerosis / diagnostic imaging
Multiple Sclerosis / drug therapy*
Prospective Studies
Treatment Outcome

Substances

ADIPOQ protein, human
Adiponectin
Biomarkers
Immunologic Factors
LEP protein, human
Leptin
Interferon-beta